xeljanz
pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
bovilis blue-8
intervet international b.v. - lammaste katarraalse palaviku viiruse vaktsiin, serotüüp 8 (inaktiveeritud) - munarakkude immunoloogilised omadused - cattle; sheep - sheepfor aktiivse immuniseerimise lamba 2. 5-kuune vanus, et vältida viraemiat * ja vähendada lammaste katarraalse palaviku viiruse serotüüp 8 põhjustatud kliinilisi tunnuseid. cattlefor aktiivse immuniseerimise karja 2. 5 kuu vanuselt, et ennetada vereemiat *, mis on põhjustatud lammaste katarraalse palaviku viiruse serotüübist 8. * (jalgrattasuurus (ct) ≥ 36 valideeritud rt-pcr meetodil, mis viitab viiruse genoomi olemasolule).
clariscan süstelahus
ge healthcare as - gadoteerhape - süstelahus - 0,5mmol 1ml 20ml 1tk; 0,5mmol 1ml 5ml 1tk; 0,5mmol 1ml 10ml 1tk; 0,5mmol 1ml 15ml 10tk; 0,5mmol 1ml 100ml 1tk; 0,5mmol 1ml 50ml 1tk; 0,5mmol 1ml 5ml 10tk; 0,5mmol 1ml 50ml 10tk; 0,5mmol 1ml 20ml 10tk
rominervin vet süstelahus
le vet. beheer b.v. - romifidiin - süstelahus - 10mg 1ml 10ml 1tk; 10mg 1ml 10ml 6tk; 10mg 1ml 20ml 6tk; 10mg 1ml 20ml 10tk; 10mg 1ml 50ml 1tk; 10mg 1ml 20ml 1tk
sedalin gel suukaudne geel
vetoquinol biowet sp. z o.o. - atsepromasiin - suukaudne geel - 35mg 1ml 10ml 1tk
hipra gumboro gm97 suukaudse suspensiooni lüofilisaat
laboratorios hipra s.a. - lindude nakkava bursiidi (gumboro) viirusvaktsiin - suukaudse suspensiooni lüofilisaat - 1annus 5000annus 1tk; 1annus 1000annus 1tk; 1annus 5000annus 10tk
lemoxol süste-/infusioonilahuse pulber
demo s.a. - tseftasidiim - süste-/infusioonilahuse pulber - 2000mg 1tk
dormicum õhukese polümeerikattega tablett
roche eesti osaühing - midasolaam - õhukese polümeerikattega tablett - 7,5mg 10tk
pamitor 15 mg/ml infusioonilahuse kontsentraat
chiesi pharmaceuticals gmbh - pamidroonhape - infusioonilahuse kontsentraat - 15mg 1ml 6ml 1tk; 15mg 1ml 4ml 1tk; 15mg 1ml 2ml 4tk; 15mg 1ml 1ml 4tk; 15mg 1ml 2ml 1tk; 15mg 1ml 4ml 4tk
nulbia kreem
nassington limited - lidokaiin+prilokaiin - kreem - 25mg+25mg 1g 5g 5tk; 25mg+25mg 1g 5g 1tk